MedTrace Logo

The Effect of Amiloride and Spironolactone in Patients With Hypertension

NCT01388088 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2012-03-28

No results posted yet for this study

Summary

The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone.

The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.

Conditions

Interventions

DRUG

Spironolactone

25 mg twice a day

DRUG

Amiloride

5 mg twice a day

DRUG

Placebo

twice a day

Sponsors & Collaborators

  • Erling Bjerregaard Pedersen

    lead OTHER

Principal Investigators

  • Solveig K Matthesen, Cand.Med · Medical Research Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01388088 on ClinicalTrials.gov